Symptomatic effect of a long acting Lanreotide formulation in patients with gastrointestinal neuroendocrine tumours.

被引：0
|
作者：
Jacobsen, MB [1 ]
deVries, EGE [1 ]
Eriksson, B [1 ]
Fiasse, R [1 ]
Wijmenga, M [1 ]
Salmela, P [1 ]
Valimaki, M [1 ]
Oberg, K [1 ]
Renstrup, J [1 ]
机构：
[1] UNIV OSLO, OSLO, NORWAY
来源：
GASTROENTEROLOGY | 1996年 / 110卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A535 / A535
页数：1
相关论文
共 50 条
  • [31] Clinicopathological characteristics and long-term outcome of gastrointestinal neuroendocrine tumours in Germany
    Maasberg, S.
    Rinke, A.
    Ezziddin, S.
    Quietzsch, D.
    Barth, C.
    Pavel, M.
    Weber, M.
    Grabowski, P.
    Bohle, W.
    Pape, U. -F
    ONKOLOGIE, 2010, 33 : 66 - 66
  • [32] EXPLORING GASTROINTESTINAL SYMPTOMS AND THEIR IMPACT ON QUALITY OF LIFE IN PATIENTS WITH NEUROENDOCRINE TUMOURS
    Williams, M.
    Reid, K.
    Lewis, J.
    Christian, A.
    Sunderraj, L.
    Williams, H.
    Rees, A.
    Khan, M. S.
    GUT, 2016, 65 : A216 - A216
  • [33] A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours
    McMullen, Todd
    Al-Jahdali, Akram
    de Gara, Christopher
    Ghosh, Sunita
    McEwan, Alexander
    Schiller, Daniel
    CANADIAN JOURNAL OF SURGERY, 2017, 60 (03) : 192 - 197
  • [34] Exploring Gastrointestinal Symptoms and Their Impact on Quality of Life in Patients with Neuroendocrine Tumours
    Williams, M.
    Reid, K.
    Ng, S.
    Benny, A.
    Lewis, J.
    Sunderraj, L.
    Williams, H.
    Rees, A.
    Khan, M.
    NEUROENDOCRINOLOGY, 2016, 103 : 120 - 121
  • [35] QUALITY OF LIFE (QOL) WITH LANREOTIDE DEPOT (LAN) VS PLACEBO IN PATIENTS WITH PANCREATIC AND GASTROINTESTINAL NEUROENDOCRINE TUMOURS: RESULTS FROM THE CLARINET PHASE III STUDY.
    Iwasaki, Michiko
    Phan, Alexandria
    Caplin, Martyn
    Ruszniewski, Philippe
    Pavel, Marianne
    Gomez-Panzani, Edda
    ONCOLOGY NURSING FORUM, 2015, 42 (02) : E144 - E144
  • [36] Malignant hypercalcaemia in patients with neuroendocrine tumours. Report of 2 cases of parathyroid hormone-related peptide-secreting pancreatic tumours
    Felipe Fierro-Maya, Luis
    Mejia-Vidal, Liliana
    Andres Quintero-Cadavid, Camilo
    Tapiero-Garcia, Mireya
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2018, 22 (04): : 162 - 168
  • [37] High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects
    Eriksson, B
    Renstrup, J
    Imam, H
    Oberg, K
    ANNALS OF ONCOLOGY, 1997, 8 (10) : 1041 - 1044
  • [38] Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
    Koumarianou, Anna
    Antoniou, Stavroula
    Kanakis, George
    Economopoulos, Nikolaos
    Rontogianni, Dimitra
    Ntavatzikos, Anastasios
    Tsavaris, Nikolaos
    Pectasides, Dimitrios
    Dimitriadis, George
    Kaltsas, Gregory
    ENDOCRINE-RELATED CANCER, 2012, 19 (01) : L1 - L4
  • [39] Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly
    Ambrosio, MR
    Franceschetti, P
    Bondanelli, M
    Doga, M
    Maffei, P
    Baldelli, R
    Tamburrano, G
    Sicolo, N
    Giustina, A
    degli Uberti, E
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (03): : 387 - 393
  • [40] The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly
    AlMaskari, M
    Gebbie, J
    KendallTaylor, P
    CLINICAL ENDOCRINOLOGY, 1996, 45 (04) : 415 - 421
12345